Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2875
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali ; volume:16 ; number:1 ; day:2 ; month:2 ; year:2017 ; pages:1-6 ; date:12.2017
Malaria journal ; 16, Heft 1 (2.2.2017), 1-6, 12.2017
- Urheber
-
Dama, Souleymane
- Beteiligte Personen und Organisationen
-
Niangaly, Hamidou
Ouattara, Amed
Sagara, Issaka
Sissoko, Sekou
Traore, Oumar Bila
Bamadio, Amadou
Dara, Niawanlou
Djimde, Moussa
Alhousseini, Mohamed Lamine
Goita, Siaka
Maiga, Hamma
Dara, Antoine
Doumbo, Ogobara K.
Djimde, Abdoulaye A.
SpringerLink (Online service)
- DOI
-
10.1186/s12936-017-1700-8
- URN
-
urn:nbn:de:101:1-2018091517060026051890
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dama, Souleymane
- Niangaly, Hamidou
- Ouattara, Amed
- Sagara, Issaka
- Sissoko, Sekou
- Traore, Oumar Bila
- Bamadio, Amadou
- Dara, Niawanlou
- Djimde, Moussa
- Alhousseini, Mohamed Lamine
- Goita, Siaka
- Maiga, Hamma
- Dara, Antoine
- Doumbo, Ogobara K.
- Djimde, Abdoulaye A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Trends in Artemether-Lumefantrine resistance of Plasmodium falciparum in Southern Rwanda
Plasmodium falciparum gametocyte dynamics after pyronaridine–artesunate or artemether–lumefantrine treatment
A randomized trial of dihydroartemisinin–piperaquine versus artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali
In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia
Efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Nepal
Therapeutic efficacy of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015–2016
Surveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in Tanzania
Therapeutic efficacy and tolerability of artemether–lumefantrine for uncomplicated Plasmodium falciparum malaria in Niger, 2020
Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018
Safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy: a systematic review
Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether–lumefantrine
Artemether–lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania
Trends in Artemether-Lumefantrine resistance of Plasmodium falciparum in Southern Rwanda
Plasmodium falciparum gametocyte dynamics after pyronaridine–artesunate or artemether–lumefantrine treatment
A randomized trial of dihydroartemisinin–piperaquine versus artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali
In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia
Efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Nepal
Therapeutic efficacy of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015–2016
Surveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in Tanzania
Therapeutic efficacy and tolerability of artemether–lumefantrine for uncomplicated Plasmodium falciparum malaria in Niger, 2020
Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018
Safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy: a systematic review
Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether–lumefantrine
Artemether–lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania
Trends in Artemether-Lumefantrine resistance of Plasmodium falciparum in Southern Rwanda
Plasmodium falciparum gametocyte dynamics after pyronaridine–artesunate or artemether–lumefantrine treatment
A randomized trial of dihydroartemisinin–piperaquine versus artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali
In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia
Efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Nepal
Therapeutic efficacy of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015–2016
Surveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in Tanzania
Therapeutic efficacy and tolerability of artemether–lumefantrine for uncomplicated Plasmodium falciparum malaria in Niger, 2020
Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018
Safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy: a systematic review
Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether–lumefantrine